The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence
Open accessAbstract
Recent reports have highlighted the distinct roles and occasional tension between randomised controlled trials (RCTs) and population-based observational research ( Concato, 2012 ; Hershman and Wright, 2012 ; Goodwin et al, 2013 ). In this commentary, we will discuss the relative strengths and limitations of each form of research (see Table 1 ), and propose that well-designed RCTs and population-based observational studies can serve as complementary forms of research to ensure that the results of clinical trials translate into tangible benefits in the general population. Table 1 An overview of relative strengths and limitations of randomized controlled trials and population-based observational studies Full size table
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
The quality of health care delivered to adults in the United States
McGlynn, E. A., Asch, S. M., Adams, J., Keesey, J., Hicks, J., DeCristofaro, A., & Kerr, E. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmsa022615 · Cited by 5,079
Hospital Volume and Surgical Mortality in the United States
Birkmeyer, J. D., Siewers, A. E., Finlayson, E. V. A., Stukel, T. A., Lucas, F. L., Batista, I., Welch, H. G., & Wennberg, D. E. (2002) · New England Journal of Medicine · doi:10.1056/nejmsa012337 · Cited by 4,999
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“…major difference in generalisability between RCTs that report substantial gain and limited toxicity (e.g., abiraterone for advanced prostate cancer (de Bono et al, 2011), adjuvant traztuzumab for breast cancer (Romond et al, 2005)) and RCTs evaluating drugs with marginal effects and substantial…”
BackgroundRisk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974 · cited 1×
“…disease and diabetes among men treated with androgen deprivation for localised prostate cancer (Keating et al, 2006), the risks of cardiac disease after radiotherapy for breast cancer (Darby et al, 2013), and long-term toxicities associated with treatment of testicular cancer (Fossa et al, 2007).”
BackgroundHuman Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
Chaturvedi, A. K., Engels, E. A., Pfeiffer, R. M., Hernandez, B. Y., Xiao, W., Kim, E., Jiang, B., Goodman, M. T., Sibug-Saber, M., Cozen, W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4596 · Cited by 3,638
Users' guides to the medical literature
Guyatt, G. H. (1993) · JAMA · doi:10.1001/jama.270.17.2096 · Cited by 2,970
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A., & Albain, K. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912303412706 · Cited by 2,174
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
Devesa, S. S., Blot, W. J., & Fraumeni, J. F. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981115)83:10<2049::aid-cncr1>3.0.co;2-2 · Cited by 2,115
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., & Redelmeier, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040135 · Cited by 1,761
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
Lewis, J. H., Kilgore, M. L., Goldman, D. P., Trimble, E. L., Kaplan, R., Montello, M. J., Housman, M. G., & Escarce, J. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.010 · Cited by 1,031
Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer
Cooperberg, M. R., Broering, J. M., & Carroll, P. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0133 · Cited by 1,006
Racial Differences in the Treatment of Early-Stage Lung Cancer
Bach, P. B., Cramer, L. D., Warren, J. L., & Begg, C. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411606 · Cited by 994
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Boutron, I. (2010) · JAMA · doi:10.1001/jama.2010.651 · Cited by 842 · cited 1×
“…therapy is providing benefit to patients when there is no difference in the primary outcome measure as compared with the control arm and/or increased toxicity associated with the new treatment (Ohorodnyk et al, 2009; Boutron et al, 2010; Altwairgi et al, 2012; Vera-Badillo et al, 2013).”
BackgroundThe uncertainty principle and industry-sponsored research
Djulbegovic, B., Lacevic, M., Cantor, A., Fields, K. K., Bennett, C. L., Adams, J. R., Kuderer, N. M., & Lyman, G. H. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02605-2 · Cited by 482
Lohrisch, C., Paltiel, C., Gelmon, K., Speers, C., Taylor, S., Barnett, J., & Olivotto, I. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6089 · Cited by 373
Chen, S. L., & Bilchik, A. J. (2006) · Transactions of the ... Meeting of the American Surgical Association · doi:10.1097/01.sla.0000237655.11717.50 · Cited by 366
Johnson, P. M., Porter, G. A., Ricciardi, R., & Baxter, N. N. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8866 · Cited by 358
Kerkhofs, T. M. A., Verhoeven, R. H. A., Van der Zwan, J. M., Dieleman, J., Kerstens, M. N., Links, T. P., Van de Poll-Franse, L. V., & Haak, H. R. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.034 · Cited by 341
Trends in the Treatment of Ductal Carcinoma In Situ of the Breast
Baxter, N. N., Virnig, B. A., Durham, S. B., & Tuttle, T. M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh069 · Cited by 334
Factors Associated With Failure to Publish Large Randomized Trials Presented at an Oncology Meeting
Krzyzanowska, M. K. (2003) · JAMA · doi:10.1001/jama.290.4.495 · Cited by 314
Racial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer
Hershman, D., McBride, R., Jacobson, J. S., Lamerato, L., Roberts, K., Grann, V. R., & Neugut, A. I. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.633 · Cited by 308
Patient Income Level and Cancer Clinical Trial Participation
Unger, J. M., Hershman, D. L., Albain, K. S., Moinpour, C. M., Petersen, J. A., Burg, K., & Crowley, J. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.4553 · Cited by 290
Dans, A. L., Dans, L. F., Guyatt, G. H., Richardson, S., & for the Evidence-Based Medicine Working Group (1998) · JAMA · doi:10.1001/jama.279.7.545 · Cited by 257
Woolf, S. H. (2005) · The Annals of Family Medicine · doi:10.1370/afm.406 · Cited by 208 · cited 2×
“…use of current treatments by giving the right treatment to the right patient at the right time, health outcomes in the general population would almost certainly improve far more than the cumulative treatment advances of countless new overpowered RCTs (McGlynn et al, 2003; Woolf and Johnson, 2005).”
BackgroundNoncancer Causes of Death in Survivors of Testicular Cancer
Fossa, S. D., Gilbert, E., Dores, G. M., Chen, J., McGlynn, K. A., Schonfeld, S., Storm, H., Hall, P., Holowaty, E., Andersen, A., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk111 · Cited by 197
Wu, X.-C., Lund, M. J., Kimmick, G. G., Richardson, L. C., Sabatino, S. A., Chen, V. W., Fleming, S. T., Morris, C. R., Huang, B., Trentham-Dietz, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8399 · Cited by 190
The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs
Niraula, S., Seruga, B., Ocana, A., Shao, T., Goldstein, R., Tannock, I. F., & Amir, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3824 · Cited by 167
Self-citationEvolution of the Randomized Controlled Trial in Oncology Over Three Decades
Booth, C. M., Cescon, D. W., Wang, L., Tannock, I. F., & Krzyzanowska, M. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5456 · Cited by 162
Self-citationDelay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women
Hershman, D. L., Wang, X., McBride, R. B., Jacobson, J. S., Grann, V. R., & Neugut, A. I. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9206-z · Cited by 157
Derogar, M., Sadr‐Azodi, O., Johar, A. M., Lagergren, P., & Lagergren, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.1517 · Cited by 150
Comparative Effectiveness Research in Oncology Methodology: Observational Data
Hershman, D. L., & Wright, J. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6701 · Cited by 132
Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.
Peppercorn, J., Blood, E., Winer, E., & Partridge, A. (2007) · Cancer · doi:10.1002/cncr.22528 · Cited by 123
Does a centralized radiotherapy system provide adequate access to care?
Mackillop, W. J., Groome, P. A., Zhang-Solomons, J., Zhou, Y., Feldman‐Stewart, D., Paszat, L. F., Dixon, P., Holowaty, E. J., & Cummings, B. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1261 · Cited by 119
Vera-Badillo, F. E., Shapiro, R., Ocana, A., Amir, E., & Tannock, I. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mds636 · Cited by 117 · cited 1×
“…therapy is providing benefit to patients when there is no difference in the primary outcome measure as compared with the control arm and/or increased toxicity associated with the new treatment (Ohorodnyk et al, 2009; Boutron et al, 2010; Altwairgi et al, 2012; Vera-Badillo et al, 2013).”
BackgroundSelf-citationŠeruga, B., Sterling, L., Wang, L. E., & Tannock, I. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9624 · Cited by 112
Self-citationSanoff, H. K., Carpenter, W. R., Martin, C. F., Sargent, D. J., Meyerhardt, J. A., Stürmer, T., Fine, J. P., Weeks, J. C., Niland, J. C., Kahn, K. L., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr524 · Cited by 97
Management and survival of colorectal cancer in the elderly in population-based studies
Faivre, J., Lemmens, V. E. P. P., Quipourt, V., & Bouvier, A. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.008 · Cited by 94
Landrum, M. B., Keating, N. L., Lamont, E. B., Bozeman, S. R., & McNeil, B. J. (2011) · Cancer · doi:10.1002/cncr.26628 · Cited by 83
Is It Time for Medicine-Based Evidence?
Concato, J. (2012) · JAMA · doi:10.1001/jama.2012.482 · Cited by 81
Kay, A., Higgins, J., Day, A. G., Meyer, R. M., & Booth, C. M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr492 · Cited by 69
Self-citationGeneralizing the Results of Cancer Clinical Trials
Meyer, R. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8608 · Cited by 53
Progress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception
Saltz, L. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.6198 · Cited by 50
Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point?
Ohorodnyk, P., Eisenhauer, E. A., & Booth, C. M. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.05.033 · Cited by 45
Self-citationAltwairgi, A. K., Booth, C. M., Hopman, W. M., & Baetz, T. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.8319 · Cited by 43
Self-citationTam, V. C., Tannock, I. F., Massey, C., Rauw, J. M., & Krzyzanowska, M. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3922 · Cited by 34
Self-citationPresentation of Nonfinal Results of Randomized Controlled Trials at Major Oncology Meetings
Booth, C. M., Maître, A. L., Ding, K., Farn, K., Fralick, M., Phillips, C., Cescon, D. W., & Meyer, R. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8771 · Cited by 31
Self-citationThe impact of audit and feedback on nodal harvest in colorectal cancer
Porter, G. A., Urquhart, R., Bu, J., Johnson, P. M., & Grunfeld, E. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-2 · Cited by 30
Evaluation of Treatment Benefit in Journal of Clinical Oncology
Goodwin, P. J., Ballman, K. V., Small, E. J., & Cannistra, S. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.6952 · Cited by 26
Cited by
Real-World Evidence — What Is It and What Can It Tell Us?
Sherman, R. E., Anderson, S. A., Dal Pan, G. J., Gray, G. W., Gross, T., Hunter, N. L., LaVange, L., Marinac-Dabic, D., Marks, P. W., Robb, M. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmsb1609216 · Cited by 2,063
Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review
Fumery, M., Singh, S., Dulai, P. S., Gower-Rousseau, C., Peyrin-Biroulet, L., & Sandborn, W. J. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.06.016 · Cited by 500
Real-world evidence in the treatment of ovarian cancer
Eisenhauer, E. A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx443 · Cited by 344
Real-world data: towards achieving the achievable in cancer care
Booth, C. M., Karim, S., & Mackillop, W. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0167-7 · Cited by 327
Self-citationFrom Data to Causes I: Building A General Cross-Lagged Panel Model (GCLM)
Zyphur, M. J., Allison, P. D., Tay, L., Voelkle, M. C., Preacher, K. J., Zhang, Z., Hamaker, E. L., Shamsollahi, A., Pierides, D. C., Koval, P., et al. (2020) · Organizational Research Methods · doi:10.1177/1094428119847278 · Cited by 306
Metadata
- Authors
- Booth, C. M., & Tannock, I. F.
- Venue
- British Journal of Cancer
- Published
- 2014-01-14
- Volume
- 110
- Issue
- 3
- Pages
- 551-555
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2055557358
- Cited by
- 469
- References
- 54
- FWCI
- 41.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.